Skip to main content
. 2022 Apr 12;10:866627. doi: 10.3389/fbioe.2022.866627

FIGURE 5.

FIGURE 5

(A) MiR-214-containing exosomes from osteoclasts inhibited osteoblast function via ephrinA2/EphA2 recognition and can also be secreted into the blood as a biomarker for bone loss (Sun et al., 2016). (B) Schematic illustration of the mechanism that osteoblast-derived EVs pretreated with TSA enhanced the osteogenic differentiation of hBMSCs and osteoblast mineralization (Man et al., 2021). (C) 3D-printed porous PCL scaffold functionalized with VEGF@CPC-derived exosomes exhibited better osteogenic and angiogenic ability (Zha et al., 2021).